Site Initiation Visits Conducted for Heart Failure with Reduced Ejection Fraction (HFrEF) polypill Study

RemediumOne has completed the site initiation visits for the pilot phase of our project, aimed at assessing the feasibility of the study design and procedures for introducing a Heart Failure with Reduced Ejection Fraction (HFrEF) polypill. This polypill combines Guideline-Directed Medical Therapy (GDMT) into a single pill, which includes a beta blocker (BB), angiotensin receptor blocker (ARB), mineralocorticoid receptor antagonist (MRA), and sodium-glucose cotransporter 2 inhibitor (SGLT2i) to streamline treatment for undertreated patients.

Trial Design

The project is conducted in collaboration with Washington University in St. Louis and The George Institute for Global Health.

Following the pilot phase, a larger, adequately powered trial will be conducted to evaluate the effects of the HFrEF polypill on key cardiovascular outcomes.

Keep in touch for more updates.

Recent Blogs
Guest Lecture by Prof. Sanjay Patel
September 10, 2025
Collaborative Research Driving New Standards in Hypertension Care
September 8, 2025
Dr Vasee Moorthy, Head of WHO for Global Clinical Trials visit Sri Lanka
August 28, 2025
Make a difference tomorrow
Get in touch with us